Your points - 1, 3, & 4 are extremely valid. I wouldn’t be too concerned about UK approval.
Instead of your point 2, I’d add that their code of business ethics is one of the worst you will find in a public company. They are a bunch of lairs and set false expectations on so many occasions to keep retail hooked. And this hasn’t just happened two or three times, they have had a history of doing that for over a decade and wiping off shareholder money. No big pharma or credible institutional investors will ever support them moving forward. Endless dilution guaranteed.